Clinical Trials Logo

Clinical Trial Summary

The main purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and early signs of efficacy of M1069 in participants with advanced solid malignancies.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

  • Metastatic or Locally Advanced Unresectable Solid Tumors
  • Neoplasms

NCT number NCT05198349
Study type Interventional
Source EMD Serono
Status Active, not recruiting
Phase Phase 1
Start date March 2, 2022
Completion date December 14, 2023

See also
  Status Clinical Trial Phase
Terminated NCT03306420 - First-in-Human Study of MS201408-0005A as Single Agent and in Combinations Phase 1
Recruiting NCT05396833 - Study of M1774 in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) Phase 1
Recruiting NCT04170153 - M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) Phase 1